Health Professional Radio - Podcast

Eric Chan, Head of Pharmacy at Blooms The Chemist , Australia's leading community pharmacy, discusses the recent White Paper detailing its response to the COVID-19 pandemic titled "Lessons Learnt from the Frontline of a Health Emergency" and he also talks about how pharmacies are adapting to new technologies and systems to increase their offering.

Pamela Bishop, Chief Marketing Officer at Blooms The Chemist, Australia's leading community pharmacy, discusses the recent White Paper detailing its response to the COVID-19 pandemic titled "Lessons Learnt from the Frontline of a Health Emergency" and she also talks about their brand strategy.

Emmanuel Vavoulas, head of retail at Blooms The Chemist, Australia's leading community pharmacy, discusses the recent White Paper detailing its response to the COVID-19 pandemic titled "Lessons Learnt from the Frontline of a Health Emergency" that includes "Ensuring the Community’s Access to Health and Medical Supplies", such as home-delivered medicine and maintaining access for vulnerable customers.

Returning guest, Bill Rancic discusses his ongoing partnership with the Astellas Oncology C3 Prize (Changing Cancer Care) program. The C3 Prize is a global challenge to advance ideas beyond medicine that can make a big impact in the cancer community. This year, Astellas Oncology is looking for ideas that can bring solutions to everyday challenges, including concepts that can ease the increased burden of the COVID-19 pandemic on cancer care and health disparities affecting cancer patients and caregivers. The program will award $200,000 in grants and resources to help winners further advance their ideas. Applications are open from now until September 28, 2020.

Abby Westerman, founder of the b-present Foundation, winner of the Astellas Oncology 2019 C3 Prize (Changing Cancer Care) Emerging Ideas Winner, discusses the mission of the foundation which is a social support network for young adults with cancer. She talks about how the C3 Prize made it possible to launch their b-there tool, including important changes to the software recommended by reviewers, as well as the development of all content, training, and help center materials to make b-there beta available online. Astellas Oncology's 5th Annual C3 Prize has launched and applications are being accepted through September 28, 2020.

The Nanny Angel Network in Canada was the grand prize winner of the Astellas Oncology 2019 C3 Prize (Changing Cancer Care). Audrey Guth, Founder of the organization discusses her inspiration to start the network in 2009 to support mothers in cancer treatment and their children. She talks about how they have been able to continue to carry out their mission, in part due to the C3 Prize, despite COVID-19 - by delivering meals, virtual visits, a “Homework Club” to assist with homework and prepare for tests and an online support group with a nurse navigator for moms. Astellas Oncology's 5th Annual C3 Prize has launched and applications are being accepted through September 28, 2020.

Leading cardiologist, Dr. Ross Walker, discusses a new study published in "Heart, Lung and Circulation" (published by Elsevier for the Australian and New Zealand Society of Cardiac and Thoracic Surgeons and the Cardiac Society of Australia and New Zealand) that evaluates ubiquinol, the active form of the powerful antioxidant CoEnzyme Q10, for heart health in patients who are taking cholesterol management medication.

Jay Baker, President of Jamestown Plastics™, a custom manufacturer of thermoformed products, talks about how he and his team did a "pandemic pivot" and created and manufactured face shields to prevent the spread of coronavirus. Jay felt it was his responsibility to immediately help create a solution that would address the needs of First Responders to be safe within his local community. Thus, True Hero™ Extreme Coverage Shield was born.

Dr. Thorsten Leucker, Assistant Professor of Medicine in the Division of Cardiology, Department of Medicine at the Johns Hopkins University School of Medicine discusses a study, EVACS (Evolocumab in Acute Coronary Syndrome) evaluating a hospital-based intervention option in ACS patients that was published in the American Heart Association’s journal, "Circulation". The study examined LDL-C reduction in non-ST-elevation myocardial infarction (NSTEMI) patients that met certain criteria.

Returning guest, Dr. Kimberly Smith, Head of Research and Development at ViiV Healthcare discusses recent advancements made in HIV studies and the impact COVID-19 has had on R&D efforts.

Dr. Barbara White, Chief Medical Officer at Corbus Pharmaceuticals discusses Lenabasum, Corbus' lead drug candidate that activates the often underutilized endocannabinoid system (ECS) to treat systemic sclerosis. Its Phase III trial recently completed treatment and is projected to release its data by the end of summer 2020.

Dr. Paul Wotton, CEO of Obsidian Therapeutics, discusses Obsidian’s platform, cytoDRiVE™, that regulates protein levels in cell and gene therapies, creating an “operating system” for living drugs. This means that now, and for the first time, physicians will be able to control genetically-engineered cells’ biologic activity to increase efficacy and reduce toxicity, using easily accessed generics and other FDA-approved drugs.

Returning guest, Daniel Simon, SVP, BioPharma Business Development at Guardant Health, a leading precision oncology company discusses a strategic collaboration with Radius Health for the commercialization and use of the Guardant360® CDx liquid biopsy companion diagnostic for elacestrant (RAD1901), an investigational therapy being studied for the treatment of advanced breast cancer in combination with hormone therapy.

Dr. Dennis Hruby, Ph.D., Chief Scientific Officer at SIGA Technologies, Inc., discusses lessons we are currently learning from the COVID-19 pandemic and whether America will be truly prepared for the next pandemic based on this one. He also talks about how healthcare will change in the future as a result of the current pandemic.

Dr. Phillip Gomez, Ph.D., CEO at SIGA Technologies, Inc., discusses how the field of Health Security has transformed after the anthrax attacks in the United States in late 2001. He also talks about the potential for a smallpox bioterror attack and how would it compare with the current COVID-19 pandemic.

Peter Rosenberger, the host of the national radio show "Hope For The Caregiver" and caregiver for over 34 years to his wife Gracie (a double amputee) who recently recovered from COVID-19, discusses his testing positive for COVID-19 three months after his wife's recovery.

Rich Birhanzel, senior managing director at Accenture who leads the company’s global health practice, discusses a recent Accenture report called "Breakthrough Behavioral Health Access: Think Virtual”. The report finds that the use of virtual delivery channels could expand treatment to millions.

Ken Perez, VP of Healthcare Policy for Omnicell discusses the launch of Omnicell One, the first tech-enabled service for health system pharmacies that leverages cloud-based data and predictive intelligence.

Chris Bradley, CEO of Loki Therapeutics discusses Loki's proprietary AWAKE™ strategy that completely bypasses the major challenges faced by traditional immunotherapy approaches. AWAKE reactivates and redirects pre-existing, life-long Memory T-cells created during childhood vaccination to target and eliminate cancer cells rather than training naïve T-cells against tumor antigens like traditional immunotherapy.

Returning guest, Dr. Ray Costantini, CEO and co-founder of Bright.md, discusses AI's role in screening for the coronavirus and their recently released COVID-19 Screener that has been offered for free in the US. He also talks about the popularity and challenges of telehealth during COVID-19 and how health systems can fill the gaps with non-video asynchronous care.